Immutep announces data from EFTISARC-NEO trial

Immutep (IMMP) announces positive data from the EFTISARC-NEO trial that were detailed in an oral presentation by Pawe Sobczuk, M.D., Ph.D., Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, at the Connective Tissue Oncology Society, CTOS, 2025 Annual Meeting held in Boca Raton, Florida. The investigator-initiated Phase II study evaluating eftilagimod alfa with radiotherapy plus KEYTRUDA in the neoadjuvant setting for resectable soft tissue sarcoma significantly exceeded the study’s prespecified level of pathologic response rates. In the evaluable patient population, the novel combination with efti reached a median 51.5% tumour hyalinization/fibrosis, meeting the study’s primary endpoint.